31 July 2025
31 July 2025
Analysts say the departure of the CBER head may alleviate overhang in the cell and gene therapy space.
Sales of GSK’s specialist oncology assets have risen by 42%, while general drug sales were down 6%.
The WHO's director-general says leaders want self-reliance, with tobacco and alcohol tax rises on the cards to boost domestic revenue.
The state’s independent body approved resolutions stating that both drugs present affordability challenges.
Kissei will take over all responsibilities related to development, regulatory processes and commercialisation in Japan.
The companies will work to advance ATB102 to treat inflammatory bowel disease.
CEO-to-be Maziar Mike Doustdar will need to stem the company’s tumbling share price as market pressures intensify.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
